PLRS-FDA-ZULASSUNG für klinische Tests - 500 Beiträge pro Seite
eröffnet am 08.02.07 12:39:23 von
neuester Beitrag 27.03.07 21:59:17 von
neuester Beitrag 27.03.07 21:59:17 von
Beiträge: 76
ID: 1.110.643
ID: 1.110.643
Aufrufe heute: 0
Gesamt: 11.539
Gesamt: 11.539
Aktive User: 0
ISIN: US72940P1066
Feedback
PLRS -- Pluristem Life Systems, Inc.
Com ($0.00001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Pluristem Announces US FDA Acceptance of its Pre-IND Application to begin Pre-clinical Studies using PLX- I in Hematological Malignancies
NEW YORK, Feb 08, 2007 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of non personalized stem cell products for a variety of indications, today announced that the United States Food and Drug Administration's (FDA) Center for Biological Evaluation and Research (CBER) accepted the Company's proposed Pre-Investigation New Drug (PreIND) for its PLX-I product in pre-clinical studies for the treatment of hematological malignancies.
PLX-I is an innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells. PLX- I is expected to be used to improve the engraftment of Umbilical Cord Blood when treating blood cancer and blood disorders. Acceptance of the Pre-IND document by the FDA precedes initiation of Phase I trials.
Zami Aberman, CEO of Pluristem, stated, "We are pleased to receive FDA's acceptance of our proposed pre-clinical studies, which may then pave the way for initiating human clinical trials during 2007. The meeting results prove the ability of our team to meet its target milestones. We are enthusiastic about the potential of our placental derived MSCs to become a superior alternative to bone marrow transplantation. We designed PLX-I to improve umbilical cord blood (UCB) engraftment, which if successful could be the key to resolving the global shortage of bone marrow tissue matching for transplantation."
"We believe that our placental derived Mesenchymal Stems Cells (MSCs), which are expanded using the Company's unique PluriX technology, may be useful for disorders other than hematological malignancies. Recently we announced that our research provided evidence that PLX cells are "immune privileged," which means they are invisible to a transplant recipient's immune system and do not trigger rejection enabling the use of PLX cells to treat other disorders."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing of non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. PLX-I, its first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
For more information, please visit our website: www.pluristem.com.
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that FDA's acceptance of our proposed pre-clinical studies may pave the way for initiating human clinical trials during 2007; that our placental derived MSCs have the potential to become a superior alternative to bone marrow transplantation; that our first products will be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation; that PLX-I could be the key to resolving the global shortage of bone marrow tissue matching for transplantation; that our unique PluriX technology may be useful for disorders other than hematological malignancies. Factors which may prevent these forward looking statements from coming to fruition include that our technology may not be validated as we progress further; our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
SOURCE: Pluristem Life Systems, Inc.
CONTACT: Pluristem Life Systems
Investor Contacts
Sr. VP Corporate Development
Dr. William Prather, 303-883-4954
bill@pluristem.com
or
Segue Ventures LLC
Craig Bird, 215-885-4981
CHBird@segue.biz
Investors' Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
or
Media Contact
Emerson Gerard Associates
Jerry Jennings, 561-881-7318
mediareply@emersongerard.com
Copyright Business Wire 2007
-0-
KEYWORD: United States
Israel
North America
Africa/Middle East
INDUSTRY KEYWORD: Health
Biotechnology
Clinical Trials
Pharmaceutical
Search for Dun & Bradstreet reports on this c
Com ($0.00001)
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Pluristem Announces US FDA Acceptance of its Pre-IND Application to begin Pre-clinical Studies using PLX- I in Hematological Malignancies
NEW YORK, Feb 08, 2007 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of non personalized stem cell products for a variety of indications, today announced that the United States Food and Drug Administration's (FDA) Center for Biological Evaluation and Research (CBER) accepted the Company's proposed Pre-Investigation New Drug (PreIND) for its PLX-I product in pre-clinical studies for the treatment of hematological malignancies.
PLX-I is an innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells. PLX- I is expected to be used to improve the engraftment of Umbilical Cord Blood when treating blood cancer and blood disorders. Acceptance of the Pre-IND document by the FDA precedes initiation of Phase I trials.
Zami Aberman, CEO of Pluristem, stated, "We are pleased to receive FDA's acceptance of our proposed pre-clinical studies, which may then pave the way for initiating human clinical trials during 2007. The meeting results prove the ability of our team to meet its target milestones. We are enthusiastic about the potential of our placental derived MSCs to become a superior alternative to bone marrow transplantation. We designed PLX-I to improve umbilical cord blood (UCB) engraftment, which if successful could be the key to resolving the global shortage of bone marrow tissue matching for transplantation."
"We believe that our placental derived Mesenchymal Stems Cells (MSCs), which are expanded using the Company's unique PluriX technology, may be useful for disorders other than hematological malignancies. Recently we announced that our research provided evidence that PLX cells are "immune privileged," which means they are invisible to a transplant recipient's immune system and do not trigger rejection enabling the use of PLX cells to treat other disorders."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing of non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. PLX-I, its first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
For more information, please visit our website: www.pluristem.com.
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that FDA's acceptance of our proposed pre-clinical studies may pave the way for initiating human clinical trials during 2007; that our placental derived MSCs have the potential to become a superior alternative to bone marrow transplantation; that our first products will be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation; that PLX-I could be the key to resolving the global shortage of bone marrow tissue matching for transplantation; that our unique PluriX technology may be useful for disorders other than hematological malignancies. Factors which may prevent these forward looking statements from coming to fruition include that our technology may not be validated as we progress further; our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
SOURCE: Pluristem Life Systems, Inc.
CONTACT: Pluristem Life Systems
Investor Contacts
Sr. VP Corporate Development
Dr. William Prather, 303-883-4954
bill@pluristem.com
or
Segue Ventures LLC
Craig Bird, 215-885-4981
CHBird@segue.biz
Investors' Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
or
Media Contact
Emerson Gerard Associates
Jerry Jennings, 561-881-7318
mediareply@emersongerard.com
Copyright Business Wire 2007
-0-
KEYWORD: United States
Israel
North America
Africa/Middle East
INDUSTRY KEYWORD: Health
Biotechnology
Clinical Trials
Pharmaceutical
Search for Dun & Bradstreet reports on this c
Antwort auf Beitrag Nr.: 27.508.713 von aloevera2750 am 08.02.07 12:42:5312.00 UHR MEZ
Antwort auf Beitrag Nr.: 27.508.888 von aloevera2750 am 08.02.07 12:48:37Auf die Meldung warten viele 
Trading Spotlight
Antwort auf Beitrag Nr.: 27.508.912 von Qork am 08.02.07 12:49:34da kann ich leider nicht mitmachen da es in deutschland nicht gehandelt wird schade
Antwort auf Beitrag Nr.: 27.508.984 von aloevera2750 am 08.02.07 12:52:00Jetzt Überweise endlich mal Geld,hast die letzte Zeit doch genug Verdient 
Antwort auf Beitrag Nr.: 27.509.022 von Qork am 08.02.07 12:53:42da hast du acuh wieder recht 
hast du gestern mitbekommen mit pradigm
hast du gestern mitbekommen mit pradigm
Antwort auf Beitrag Nr.: 27.509.117 von aloevera2750 am 08.02.07 12:57:16Ich VOLLKOFFER war zu geizig bei 0,012 reinzugehen weil ich dachte der Zock war schon
Antwort auf Beitrag Nr.: 27.509.172 von Qork am 08.02.07 12:59:44ich hatte denn mut bin noch zu 0,015 rein und heute morgen rausgespühlt mit 0,039
Antwort auf Beitrag Nr.: 27.509.220 von aloevera2750 am 08.02.07 13:01:19Du ARmer hättest auch 5 kriegen können
Antwort auf Beitrag Nr.: 27.509.245 von Qork am 08.02.07 13:02:14ich war ja nicht da einer muss ja arbeiten
einer muss ja arbeiten
Die Meldung von Heute ist darauf bezogen,also haben die Investoren lange genug drauf gewartet,so das es Heute einen Hype geben könnte
HAIFA, Israel, Oct 31, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (PLRS) , a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company\'s innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).
In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem\'s Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.
HAIFA, Israel, Oct 31, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (PLRS) , a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company\'s innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).
In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem\'s Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.
Antwort auf Beitrag Nr.: 27.509.172 von Qork am 08.02.07 12:59:44Der Zock da drüben ist doch immer noch. Kommt heut nur auf US an. Drüben 100% plus.
Hier könnte aber auch was gehen.Schade hab gerade letztes Cash in Fonix gesteckt.
Hier könnte aber auch was gehen.Schade hab gerade letztes Cash in Fonix gesteckt.
Antwort auf Beitrag Nr.: 27.510.762 von schnorps01 am 08.02.07 14:04:18Ich gehe aber in keine Aktie die schon 710.26% gelaufen ist
Antwort auf Beitrag Nr.: 27.511.096 von axcol am 08.02.07 14:17:09Du meinst beim Verkauf ++++++++ 710%
Antwort auf Beitrag Nr.: 27.511.201 von Qork am 08.02.07 14:22:08ich schau mal weiter....
ob ich kaufe
ob ich kaufe
Outstanding Shares: 66,629,663 as of 2006-09-05
MK nur ca. 1,7 Mio USD !!!!
Da geht heute was!!!!
MK nur ca. 1,7 Mio USD !!!!
Da geht heute was!!!!
Recent Trades - Last 7
Time Ex Price Change Volume
09:24:56 Q 0.03 +0.004 15,000
09:18:06 Q 0.03 +0.004 20,000
09:18:01 Q 0.03 +0.004 20,000
09:17:22 Q 0.03 +0.004 5,000
09:16:44 Q 0.03 +0.004 2,500
09:16:41 Q 0.03 +0.004 5,000
09:16:35 Q 0.03 +0.004 5,000
Time Ex Price Change Volume
09:24:56 Q 0.03 +0.004 15,000
09:18:06 Q 0.03 +0.004 20,000
09:18:01 Q 0.03 +0.004 20,000
09:17:22 Q 0.03 +0.004 5,000
09:16:44 Q 0.03 +0.004 2,500
09:16:41 Q 0.03 +0.004 5,000
09:16:35 Q 0.03 +0.004 5,000
Time Ex Price Change Volume
09:28:38 Q 0.032 +0.006 49,178
09:27:47 Q 0.031 +0.005 50,000
09:26:50 Q 0.031 +0.005 30,000
09:25:39 Q 0.03 +0.004 35,000
09:24:56 Q 0.03 +0.004 15,000
09:18:06 Q 0.03 +0.004 20,000
09:18:01 Q 0.03 +0.004 20,000
09:28:38 Q 0.032 +0.006 49,178
09:27:47 Q 0.031 +0.005 50,000
09:26:50 Q 0.031 +0.005 30,000
09:25:39 Q 0.03 +0.004 35,000
09:24:56 Q 0.03 +0.004 15,000
09:18:06 Q 0.03 +0.004 20,000
09:18:01 Q 0.03 +0.004 20,000
Time Ex Price Change Volume
09:29:03 Q 0.033 +0.007 50,000
09:28:38 Q 0.032 +0.006 49,178
09:27:47 Q 0.031 +0.005 50,000
09:26:50 Q 0.031 +0.005 30,000
09:29:03 Q 0.033 +0.007 50,000
09:28:38 Q 0.032 +0.006 49,178
09:27:47 Q 0.031 +0.005 50,000
09:26:50 Q 0.031 +0.005 30,000
so bin dabei zu 0,032$
mal sehen wie die heute noch ins laufen kommt!
mal sehen wie die heute noch ins laufen kommt!
Antwort auf Beitrag Nr.: 27.513.338 von Marchella am 08.02.07 15:39:04Bin auch dabei........
Mal schauen was´die USA heute so macht..
Mal schauen was´die USA heute so macht..
Antwort auf Beitrag Nr.: 27.513.393 von URANI am 08.02.07 15:41:24So bin auch dabei..
Kann losgehen
Grüße
Kann losgehen
Grüße
Antwort auf Beitrag Nr.: 27.513.641 von UH1d am 08.02.07 15:48:03na dann sind wir ja schon zu dritt
nr 4....
Moin,
bin auch dabei
bin auch dabei
Antwort auf Beitrag Nr.: 27.513.775 von axcol am 08.02.07 15:51:33Mahlzeit
Die kommt heute noch ins rollen warten wir mal ein wenig
Die kommt heute noch ins rollen
warten wir mal ein wenig
Antwort auf Beitrag Nr.: 27.513.900 von Marchella am 08.02.07 15:54:57Aber nur ein wenig.......
Detailed Quote for Thursday, February 08, 2007 1:12 PM
Company Name: Pluristem Life Sys Inc
Dow Jones Industry: Biotechnology
Exchange: OTC BB
Shares Outstanding: 77,320,000
Market Cap: 2.4 Million
Short Interest: Exchange provides no short interest data.
52-Week EPS: -0.03
52-Week High: 0.11 on Friday, February 24, 2006
52-Week Low: 0.012 on Friday, November 24, 2006
P/E Ratio: n/a
Yield: n/a
Average Price: 0.0185 (50-day) 0.0322 (200-day)
Average Volume: 5,575,100 (50-day) 4,818,700 (200-day)
Company Name: Pluristem Life Sys Inc
Dow Jones Industry: Biotechnology
Exchange: OTC BB
Shares Outstanding: 77,320,000
Market Cap: 2.4 Million
Short Interest: Exchange provides no short interest data.
52-Week EPS: -0.03
52-Week High: 0.11 on Friday, February 24, 2006
52-Week Low: 0.012 on Friday, November 24, 2006
P/E Ratio: n/a
Yield: n/a
Average Price: 0.0185 (50-day) 0.0322 (200-day)
Average Volume: 5,575,100 (50-day) 4,818,700 (200-day)
Antwort auf Beitrag Nr.: 27.522.779 von Marchella am 08.02.07 19:37:47
Antwort auf Beitrag Nr.: 27.522.779 von Marchella am 08.02.07 19:37:47Market Cap
7,454,464
7,454,464
Mal schauen was heute so passiert..
PLURISTEM LIFE SYSTEMS
RealPennies: Alerts: Turning Pennies into dollars: (Pink Sheets: SGCP), (OTCBB: PLRS), (Pink Sheets: MBWC), (OTCBB: ONGO).
RealPennies: Alerts: Turning Pennies into dollars: (Pink Sheets: SGCP), (OTCBB: PLRS), (Pink Sheets: MBWC), (OTCBB: ONGO).
Antwort auf Beitrag Nr.: 27.546.818 von URANI am 09.02.07 14:19:10PLURISTEM LIFE SYSTEMS
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, February 8th, SGCP, RENG, NAWL, MBWC, PLRS, RVTI
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, February 8th, SGCP, RENG, NAWL, MBWC, PLRS, RVTI
Dallas, Texas, Feb 09, 2007 (M2 PRESSWIRE via COMTEX News Network) --
StockGuru Pre-Market Updates for Friday include Ballistic Recovery Systems, Inc. (OTCBB BRSI), Nexia Holdings, Inc. (OTCBB NEXH), avVaa World Health Care Products (OTCBB AVVW), Universal Property Development and Acquisition Corporation (OTCBB UPDA), and Pluristem Life Systems, Inc. (OTCBB PLRS). StockGuru Pre-Market Updates feature companies with significant moves in either volume or price in the past two trading sessions. In our update we analyze recent news about the companies featured and detail the movement in the stock.
StockGuru Pre-Market Updates for Friday include Ballistic Recovery Systems, Inc. (OTCBB BRSI), Nexia Holdings, Inc. (OTCBB NEXH), avVaa World Health Care Products (OTCBB AVVW), Universal Property Development and Acquisition Corporation (OTCBB UPDA), and Pluristem Life Systems, Inc. (OTCBB PLRS). StockGuru Pre-Market Updates feature companies with significant moves in either volume or price in the past two trading sessions. In our update we analyze recent news about the companies featured and detail the movement in the stock.
WillyWizard.com: WillyWizard.com Reports Stocks
OTCBB: PLRS) Pluristem Life Systems, Inc.
Pluristem Announces US FDA Acceptance of its Pre-IND Application to begin Pre-clinical Studies using PLX- I in Hematological Malignancies
NEW YORK-- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of non personalized stem cell products for a variety of indications, today announced that the United States Food and Drug Administration's (FDA) Center for Biological Evaluation and Research (CBER) accepted the Company's proposed Pre-Investigation New Drug (PreIND) for its PLX-I product in pre-clinical studies for the treatment of hematological malignancies.
PLX-I is an innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells. PLX- I is expected to be used to improve the engraftment of Umbilical Cord Blood when treating blood cancer and blood disorders. Acceptance of the Pre-IND document by the FDA precedes initiation of Phase I trials.
Zami Aberman, CEO of Pluristem, stated, "We are pleased to receive FDA's acceptance of our proposed pre-clinical studies, which may then pave the way for initiating human clinical trials during 2007. The meeting results prove the ability of our team to meet its target milestones. We are enthusiastic about the potential of our placental derived MSCs to become a superior alternative to bone marrow transplantation. We designed PLX-I to improve umbilical cord blood (UCB) engraftment, which if successful could be the key to resolving the global shortage of bone marrow tissue matching for transplantation."
"We believe that our placental derived Mesenchymal Stems Cells (MSCs), which are expanded using the Company's unique PluriX technology, may be useful for disorders other than hematological malignancies. Recently we announced that our research provided evidence that PLX cells are "immune privileged," which means they are invisible to a transplant recipient's immune system and do not trigger rejection enabling the use of PLX cells to treat other disorders."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing of non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation.
PLX-I, its first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
OTCBB: PLRS) Pluristem Life Systems, Inc.
Pluristem Announces US FDA Acceptance of its Pre-IND Application to begin Pre-clinical Studies using PLX- I in Hematological Malignancies
NEW YORK-- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of non personalized stem cell products for a variety of indications, today announced that the United States Food and Drug Administration's (FDA) Center for Biological Evaluation and Research (CBER) accepted the Company's proposed Pre-Investigation New Drug (PreIND) for its PLX-I product in pre-clinical studies for the treatment of hematological malignancies.
PLX-I is an innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells. PLX- I is expected to be used to improve the engraftment of Umbilical Cord Blood when treating blood cancer and blood disorders. Acceptance of the Pre-IND document by the FDA precedes initiation of Phase I trials.
Zami Aberman, CEO of Pluristem, stated, "We are pleased to receive FDA's acceptance of our proposed pre-clinical studies, which may then pave the way for initiating human clinical trials during 2007. The meeting results prove the ability of our team to meet its target milestones. We are enthusiastic about the potential of our placental derived MSCs to become a superior alternative to bone marrow transplantation. We designed PLX-I to improve umbilical cord blood (UCB) engraftment, which if successful could be the key to resolving the global shortage of bone marrow tissue matching for transplantation."
"We believe that our placental derived Mesenchymal Stems Cells (MSCs), which are expanded using the Company's unique PluriX technology, may be useful for disorders other than hematological malignancies. Recently we announced that our research provided evidence that PLX cells are "immune privileged," which means they are invisible to a transplant recipient's immune system and do not trigger rejection enabling the use of PLX cells to treat other disorders."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven company that is developing and commercializing of non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation.
PLX-I, its first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
Hi. Was meinst Du. Geht noch was? Bisher eher nach unten.
Antwort auf Beitrag Nr.: 27.549.870 von Allister am 09.02.07 16:14:29Scwer zu sagen... Kann vielleicht sein das zwischen 20-22 Uhr noch was geht. Hätte mir ein bissel mehr erwartet..
Hatte auch mit mehr gerechnet. Scheint aber nicht so. Na ja, wir werden sehen.
NEWS !!!!!!!!!!!!!1
February 14, 2007 - 7:04 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
PLRS 0.035 0.00
Today 5d 1m 3m 1y 5y 10y
Pluristem Announces Private Equity Investment of $8M
Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy Company dedicated to the commercialization of stem cell products for a variety of indications, today announced that it has signed a binding term sheet with new investors for a private equity investment in the amount of $8,000,000. The first payment of funds totaling $1,250,000 has been received.
The investors will receive Pluristem restricted common stock at a price of $0.0125 per share and a warrant to purchase additional shares at an exercise price of $0.025 per share. The final agreement is expected to be completed by March 15, 2007.
Mr. Zami Aberman, CEO of Pluristem Life Systems stated: “We are delighted these new investors have shown their confidence in Pluristem. Our business strategy targets a potential $30 billion market by capitalizing on our proprietary PLacenta eXpanded (PLX I) and 3D PluriX™ technologies and our unique business model of “supply-on-demand” cells for a variety of clinical indications. This financing enables us to fund our activities for the next 2 years and generate the clinical data we believe will support the therapeutic effects of PLX-I in the treatment of hematological malignancies. In addition, we will explore the use of PLX-I in new clinical applications."
Pluristem developed PLX I as an allogeneic product, based on supplementing the umbilical cord blood cells with supportive cells that improve the effectiveness of engraftments and shorten recovery times. PLX I mesenchymal stem cells were proven to increase the umbilical cord blood stem cells effectiveness by 3-5 times in a pre-clinical study.
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor (PluriX™) mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the currently accepted standard procedure of bone marrow transplantation. PLX-I, Pluristem’ first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
For more information, please visit our website: www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that there is a $30 billion market potential for our products; that we expect to sign the final agreement for a $8,000,000 private placement by April,10, 2007; that we will be able to develop our “supply-on-demand” cells business model for a variety of clinical indications; and that this investment in the Company will enable us finance our activities for the next 2 years generating clinical data to support the therapeutic effects of PLX-I. Factors which may significantly change or prevent our forward looking statements from fruition include that the investors may not close the private placement or finance the remainder of the $8,000,000; we currently do not have sufficient authorized capital to complete the private placement in full and may be unable to increase our authorized capital; we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Investors:
Pluristem Life Systems
Sr. VP Corporate Development
Dr. William Prather, 303-883-4954
bill@pluristem.com
or
Segue Ventures LLC
Craig Bird, 215-885–4981
CHBird@segue.biz
Investors’ Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/
or
Media:
Emerson Gerard Associates
Jerry Jennings, 561-881-7318
mediareply@emersongerard.com
Source: Business Wire (February 14, 2007 - 7:04 AM EST)
News by QuoteMedia
www.quotemedia.com
Könnte ein dunkelgrüner Tag heute werden!
-
-
today announced that it has signed a binding term sheet with new investors for a private equity investment
in the amount of $8,000,000!!!!
8 MIO`s !!!
in the amount of $8,000,000!!!!
8 MIO`s !!!
Hallo!
Na ein Glück hab ich nicht gleich wieder verkauft, war kurz davor.
Sieht sehr gut aus denke ich!
Good Luck!
Grüße
Na ein Glück hab ich nicht gleich wieder verkauft, war kurz davor.
Sieht sehr gut aus denke ich!
Good Luck!
Grüße
"Sell on good News" scheint vorbei zu sein!!??
Wie gehts Dienstag weiter... frag ich mich!
Sieht doch gut aus bis jetzt,wir bleiben bestimmt grün!
schönes WE
Sieht doch gut aus bis jetzt,wir bleiben bestimmt grün!
schönes WE
So nach 100% Einsatz ist erstmal raus
Rest las ich mal laufen
Keiner mehr dabei?
Manchmal lohnt sich das warten
Rest las ich mal laufen
Keiner mehr dabei?
Manchmal lohnt sich das warten
Bin noch dabei!
Grüße
Grüße
Press Release Source: Pluristem Life Systems
Pluristem Life Systems, Inc. Announces First Licensing Agreement and Stock Swap With Stem Cell Innovations, Inc.
Thursday February 22, 7:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News; Pluristem) announced today a licensing agreement and stock swap with Stem Cell Innovations, Inc. (OTCBB:SCLL - News; Stem Cell) for certain marketing rights of Pluristem's PLX I product in Asia, excluding Japan and 3-D stem cell expansion capability.
ADVERTISEMENT
The licensing agreement provides Stem Cell with certain rights to Pluristem's PLX I product and 3-D stem cell expansion capability, in exchange for an upfront fee of 23 million shares of Stem Cell's common stock, milestone payments and royalties.
Stem Cell CEO Dr. James Kelly commented, "We are excited with Pluristem's 3-D stem cells expansion capability for use in conjunction with our PluriCell technology. We believe this collaboration will improve our product development capabilities, leading to better solutions for both in vivo and in vitro applications and improve our shareholder value."
"Licensing our products and capabilities is a key event in our commercialization process," stated Mr. Zami Aberman, CEO of Pluristem Life Systems. "Stem Cell's decision to license PLX I for the Asian market, excluding Japan and our 3-D expansion capability is compelling evidence that our products will be developed and sold worldwide. This agreement represents a potential multimillion dollar recurring revenue stream. We believe this collaboration will lead to several synergistic solutions, benefiting million of patients worldwide. Our 3-D technology has numerous applications that we intend to develop with Stem Cell and other companies."
Under the terms of the stock swap, Stem Cell will exchange 27 million shares of Stem Cell's common stock for 66 million shares of Pluristem common stock and five-year warrants to purchase 66 million shares of Pluristem common stock at an exercise price of $.03 per share.
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor (PluriX(TM)) mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the currently accepted standard procedure of bone marrow transplantation. PLX-I, Pluristem' first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
www.pluristem.com
Pluristem Life Systems, Inc. Announces First Licensing Agreement and Stock Swap With Stem Cell Innovations, Inc.
Thursday February 22, 7:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News; Pluristem) announced today a licensing agreement and stock swap with Stem Cell Innovations, Inc. (OTCBB:SCLL - News; Stem Cell) for certain marketing rights of Pluristem's PLX I product in Asia, excluding Japan and 3-D stem cell expansion capability.
ADVERTISEMENT
The licensing agreement provides Stem Cell with certain rights to Pluristem's PLX I product and 3-D stem cell expansion capability, in exchange for an upfront fee of 23 million shares of Stem Cell's common stock, milestone payments and royalties.
Stem Cell CEO Dr. James Kelly commented, "We are excited with Pluristem's 3-D stem cells expansion capability for use in conjunction with our PluriCell technology. We believe this collaboration will improve our product development capabilities, leading to better solutions for both in vivo and in vitro applications and improve our shareholder value."
"Licensing our products and capabilities is a key event in our commercialization process," stated Mr. Zami Aberman, CEO of Pluristem Life Systems. "Stem Cell's decision to license PLX I for the Asian market, excluding Japan and our 3-D expansion capability is compelling evidence that our products will be developed and sold worldwide. This agreement represents a potential multimillion dollar recurring revenue stream. We believe this collaboration will lead to several synergistic solutions, benefiting million of patients worldwide. Our 3-D technology has numerous applications that we intend to develop with Stem Cell and other companies."
Under the terms of the stock swap, Stem Cell will exchange 27 million shares of Stem Cell's common stock for 66 million shares of Pluristem common stock and five-year warrants to purchase 66 million shares of Pluristem common stock at an exercise price of $.03 per share.
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing non personalized stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor (PluriX(TM)) mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the currently accepted standard procedure of bone marrow transplantation. PLX-I, Pluristem' first adult stem cell product, is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
www.pluristem.com
Antwort auf Beitrag Nr.: 27.896.125 von UH1d am 22.02.07 13:04:22ganz kurz mal erkläört für nicht Englisch versierte: liest sich sehr positiv..oder liege ich da falsch..??
Antwort auf Beitrag Nr.: 27.898.251 von Daxboy5000 am 22.02.07 14:45:00Wärest Du bei Threaderöffnung zu 3 eingestiegen hättest Du schon 100% 
Antwort auf Beitrag Nr.: 27.898.251 von Daxboy5000 am 22.02.07 14:45:00Die ist sehr Positiv
Antwort auf Beitrag Nr.: 27.898.441 von Qork am 22.02.07 14:53:41Danke, habe das was verpasst
und weiter gehts
RT 0,075$
RT 0,075$
habe heute feuchte hände bekommen... sorry... Einsatz bleibt.
Antwort auf Beitrag Nr.: 27.902.277 von Jannik04 am 22.02.07 17:00:22Hi Jannik, was meinst du wie es kurz,- bis mittelfristig weitergehen wird...bin von dem Wert sehr überzeugt.
Grüsse daxboy
Grüsse daxboy
Das gleiche Szenario wie bei der letzten guten Meldung. Sell on good News und dann wieder rauf! Ich bin guter Dinge das wir heute wieder ein kräftiges grün sehen werden!
Genau wie beim letzten Mal! Da sind Typen am Werk die Massenhaft 5000der Pakete "bestens" verkaufen und somit den Kurs ruck zuck nach unten ziehen! Keine Panik!
Pluristem Announces Scientific Advance in Stem Cell Research; Evidence That PLX Cells Are Immunosuppressive
Thursday March 1, 7:00 am ET
NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products for a variety of indications, today announced that it has evidence that its PLX cells are immunosuppressive and immune privileged. These characteristics could lead to breakthroughs in the treatment of hematopoietic cancers and immune diseases. PLX cells are mesenchymal stem cells (MSCs) obtained from the placenta and expanded by using Pluristem's proprietary 3D PluriX(TM) technology.
ADVERTISEMENT
Immunosuppression is defined as the quality of a product to attenuate or suppress the effects of the immune system. Induced immunosuppression is generally practiced to prevent the body from rejecting an organ or bone marrow transplant or for the treatment of auto-immune diseases. Pluristem believes their immunosuppressive PLX cells could have significant positive implications in the development of products for a variety of therapeutic needs: regenerative medicine, physiological diseases and immune diseases. Additionally, this immune modulating property could prove important in treating or preventing immune reactions associated with transplantation.
Ora Burger PhD. V.P. of R&D at Pluristem stated: "Our PLX cells showed immune suppression characteristics during in vitro testing using Mixed Lymphocyte Reaction assay (MLR). The immunosuppressive quality is an important attribute for our first product, PLX-I, in the treatment of hematological malignancies. Additionally, it has promising indications for other applications involving the immune system."
William R. Prather RPh, MD, Sr. V.P. Corporate Development notes: "We now have evidence that our PLX cells are immunosuppressive as well as immune privileged. We believe these important characteristics underscore our belief that placenta-derived MSCs expanded three dimensionally in our PluriX(TM) bioreactor to become PLX cells are truly unique and may prove valuable in the treatment of a variety of degenerative, malignant and immune conditions."
About Pluristem
Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor termed the PluriX(TM) that mimics different naturally occurring physiological environments. Pluristem expects its first product, PLX-I, will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. PLX-I is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release, include: PLX cells are immunosuppressive; These characteristics could lead to breakthroughs in the treatment of hematopoietic cancers and immune diseases; that immunosuppressive PLX cells could have significant positive implications in the development of products for a variety of therapeutic needs: regenerative medicine, physiological diseases and immune diseases; that PLX cells possess immune suppression characteristics that may be used for other applications; that it has promising indications for other applications involving the immune system; that our proprietary PluriX(TM) bioreactor that gives us the unique capability to manufacture placenta-derived MSCs expanded three dimensionally to produce PLX cells. Factors that could prevent our forward looking statements from being achieved include: that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Contact:
großer Sport!
Hab leider den größten Teil rausgehauen.
Grüße
der Rest bleibt
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -6,35 | |
| +4,15 | |
| -21,43 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 210 | ||
| 106 | ||
| 85 | ||
| 75 | ||
| 43 | ||
| 42 | ||
| 38 | ||
| 34 | ||
| 33 | ||
| 30 |
